HUMAN IL-2
- CAS No.
- 110942-02-4
- Chemical Name:
- HUMAN IL-2
- Synonyms
- IL-2;HIL-2;C07903;RHIL-2;HUMAN TCGF;HUMAN IL-2;TCGF HUMAN;IL-2, HUMAN;aldesleukin;IL-2 from rat
- CBNumber:
- CB3161838
- Molecular Formula:
- Molecular Weight:
- 0
- MOL File:
- Mol file
- Modify Date:
- 2023/5/9 9:30:38
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P280-P302+P352-P362+P364 |
| Hazard Codes | B,Xi |
| Risk Statements | 36 |
| Safety Statements | 23-24/25-26 |
| WGK Germany | 3 |
| RTECS | NM9741332 |
| HS Code | 3504009000 |
HUMAN IL-2 price More Price(9)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | SRP8034 | IL-2 (human): FC (human) recombinant, expressed in HEK 293 cells, >95% (SDS-PAGE) | 110942-02-4 | 10μG | ₹42468.6 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SRP6170 | IL-2 human recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE) | 110942-02-4 | 10μG | ₹22333.2 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | I2644 | Interleukin-2 human IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture | 110942-02-4 | 10μG | ₹33499.8 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | SRP3085 | IL-2 human Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture | 110942-02-4 | 50μG | ₹38095.2 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | I2644 | Interleukin-2 human IL-2, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture | 110942-02-4 | 5X10μG | ₹124986 | 2022-06-14 | Buy |
HUMAN IL-2 Chemical Properties,Uses,Production
Uses
Antineoplastic; biological response modifier; immunostimulant.
Indications
Aldesleukin (IL-2, Proleukin) is a human recombinant
interleukin-2 protein. Its antitumor action is thought to
include multiple effects on the immune system, such as
enhancement of T-lymphocyte cytotoxicity, induction of
natural killer cell activity, and induction of interferon-γ
production. Aldesleukin has been used alone and in
combination with lymphokine activated killer (LAK)
cells or tumor-infiltrating lymphocytes (TIL).
The drug produces remissions in 15% of patients
with renal cell carcinoma, with median durations of remission
of 18 to 24 months.
General Description
Aldesleukin, T-cell growth factor, thymocyte-stimulatingfactor, Proleukin, is recombinant IL-2 expressed in an engineeredstrain of E. coli containing an analog of the humanIL-2 gene.Aldesleukin enhances lymphocyte mitogenesis and stimulateslong-term growth of human IL-2-dependent cell lines.
IL-2 also enhances the cytotoxicity of lymphocytes. Inductionof NK cell and lymphocyte-activated killer (LAK) cell activityoccurs, as does induction of production. In mouse andhuman tumor cell lines, aldesleukin activates cellular immunityin patients with profound lymphocytosis, eosinophilia,and thrombocytopenia. Aldesleukin also activates the productionof cytokines, including tumor necrosis factor (TNF),IL-1, and IFN-γ. In vivo experiments in mouse tumor modelshave shown inhibition of tumor growth. The mechanism ofthe antitumor effect of aldesleukin is unknown.
Aldesleukin is indicated for the treatment of metastaticrenal cell carcinoma in adults. It is also indicated for thetreatment of metastatic melanoma in adults. Research isunder way on the use of aldesleukin for the treatment of variouscancers (including head and neck cancers), treatment ofacute myelogenous leukemia, and adjunct therapy in thetreatment of Kaposi sarcoma. Renal and hepatic function istypically impaired during therapy with aldesleukin, so interactionwith other drugs that undergo elimination by these organsis possible.
Side effects
Several serious toxicities have been observed, with a fatality rate of 5% in the initial studies. The major adverse effect is severe hypotension in as many as 85% of patients, which may lead to myocardial infarctions, pulmonary edema, and strokes.This hypotension is thought to be due to a capillary leak syndrome resulting from extravasation of plasma proteins and fluid into extravascular space and a loss of vascular tone. Patients with significant cardiac, pulmonary, renal, hepatic, or CNS conditions should not receive therapy with aldesleukin. Other adverse reactions include nausea and vomiting, diarrhea, stomatitis, anorexia, altered mental status, fevers, and fatigue.
HUMAN IL-2 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Career Henan Chemica Co | +86-0371-86658258 +8613203830695 | China | 30253 | 58 | Inquiry |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 | China | 25910 | 58 | Inquiry |
| JiangSu Star Science Co.,Ltd | 400-605-7200 17312445705 | China | 3764 | 58 | Inquiry |
| Shanghai Huzhen Industrial Co., LTD | 021-60345367 13916550749 | China | 9965 | 58 | Inquiry |
| ACROBiosystems | 18514007688 | China | 976 | 58 | Inquiry |
| Shanghai Yaji Biological Technology Co., Ltd. | 021-34661275 15301693058 | China | 8440 | 58 | Inquiry |
| AntibodySystem | 17762345272 18162686757 | China | 9817 | 58 | Inquiry |
| Gongyishengan Technology (Shenzhen) Co., Ltd. | +86-0755-89218110 +86-13480856786 | China | 919 | 58 | Inquiry |
| Beijing Saibei Biotechnology Co., Ltd. | 010-69737398 | CHINA | 11 | 58 | Inquiry |
| Sigma-Aldrich | 021-61415566 800-8193336 | China | 51471 | 80 | Inquiry |
110942-02-4(HUMAN IL-2)Related Search:
1of4
chevron_right